SCHEDULE 13G/A: ARK Investment Management Discloses Significant Stake in Beam Therapeutics
Beneficial Ownership Report
ARK Investment Management LLC has filed an amended Schedule 13G, reporting a 7.92% beneficial ownership stake in Beam Therapeutics Inc. as of September 30, 2024.
Summary
- ARK Investment Management LLC, an investment adviser, has filed an Amendment No. 4 to Schedule 13G regarding its beneficial ownership in Beam Therapeutics Inc.
- As of September 30, 2024, ARK Investment Management LLC beneficially owned an aggregate of 6,531,099 shares of Beam Therapeutics Inc. Common Stock.
- This ownership represents 7.92% of the total class of securities outstanding.
- The shares are held with sole voting power over 6,268,000 shares and shared voting power over 100,578 shares.
- ARK Investment Management LLC holds sole dispositive power over all 6,531,099 shares and no shared dispositive power.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 7
Explanation: The filing indicates a significant beneficial ownership stake by a reputable investment management firm, suggesting confidence in the issuer. While not a performance report, institutional backing is generally viewed positively.
Positives
- The disclosure of a significant beneficial ownership stake by a prominent institutional investor like ARK Investment Management LLC can be interpreted as a vote of confidence in Beam Therapeutics Inc.
Future Outlook
NA
Industry Context
ARK Investment Management is known for its focus on disruptive innovation, particularly in sectors like biotechnology. Their significant stake in Beam Therapeutics Inc., a company operating in the gene editing space, aligns with their investment philosophy of targeting companies at the forefront of technological advancement.
Stakeholder Impact
- Shareholders may perceive the substantial investment by ARK Investment Management as a positive indicator, potentially bolstering investor confidence in Beam Therapeutics Inc.'s future prospects.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of event which required the filing of this statement (snapshot of ownership). |
| 01/10/2025 | Date the Schedule 13G/A filing was signed and submitted. |
Keywords
Beam Therapeutics, ARK Investment Management, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Ownership, Biotechnology, Investment Adviser, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.